Home Sera Prognostics Inc.

Sera Prognostics Inc.

Publication Demonstrates Ability of Sera Prognostics’ PreTRM® Biomarker Test as a Predictor of Adverse Pregnancy Outcomes

The results of the study, which were selected for a podium presentation at the 40th Annual Pregnancy Meeting of the Society for Maternal-Fetal Medicine in February 2020, demonstrate that the company’s PreTRM® biomarker test can be used to predict very preterm birth, (infants born before 32 weeks of gestation) as well as increased length of neonatal hospital stay and severe adverse neonatal outcomes.